EYEG Logo

EyeGate Pharmaceuticals Inc (EYEG) Stock Forecast & Price Prediction

Live EYEG Stock Price & Analysis

Home โ€บ Stocks โ€บ United States | NASDAQ | |

$35.23

-0.14 (-0.38%)

12 Month Price Forecast For EYEG

$35.23
Current Price
$161.21M
Market Cap
3 Ratings
Buy 3
Hold 0
Sell 0
Wall St Analyst Ratings

Distance to EYEG Price Forecasts

N/A
To High Target of $N/A
N/A
To Median Target of $N/A
N/A
To Low Target of $N/A

EYEG Price Momentum

+0.3%
1 Week Change
+1.8%
1 Month Change
0.0%
1 Year Change
+0.7%
Year-to-Date Change
-5.4%
From 52W High of $37.24
+2.0%
From 52W Low of $34.56

๐Ÿค” Considering EyeGate (EYEG)?

Join 5,000+ investors getting our exclusive market analysis every Monday & Thursday. Stay ahead of breakout opportunities.

Disclaimer: The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.

Data last updated: February 10, 2025 4:36 PM UTC

EYEG Analyst Ratings & Price Targets

Based on our analysis of 2 Wall Street analysts, EYEG has a consensus that is bullish. The median price target is $0.00, with forecasts ranging from $0.00 to $0.00. Currently, there are 3 Buy ratings, 0 Hold ratings, and 0 Sell ratings.

With EYEG currently trading at $35.23, the median price forecast suggests a -100.0% downside. The most optimistic forecast comes from at HC Wainwright & Co., projecting a -100.0% downside, while at HC Wainwright & Co. provides the most conservative target, suggesting a -100.0% downside.

Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.

EYEG Analyst Consensus

3
Buy
0
Hold
0
Sell

EYEG Price Target Range

Low
N/A
Average
N/A
High
N/A
Current: $35.23

Latest EYEG Stock Forecasts by Analyst

These are the latest 20 analyst ratings and price targets for EYEG.

Date Firm Analyst Rating Change Price Target
Aug 16, 2021 HC Wainwright & Co. Yi Chen Buy Maintains $11.00
Nov 12, 2020 HC Wainwright & Co. Buy Maintains $0.00
Jul 21, 2020 Alliance Global Partners Buy Initiates $0.00
May 19, 2020 HC Wainwright & Co. Buy Reiterates $0.00
Nov 15, 2017 H.C. Wainwright Buy Maintains $0.00
Apr 7, 2016 Noble Financial Buy Initiates $0.00

Stocks Similar to EyeGate Pharmaceuticals Inc

The following stocks are similar to EyeGate based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.

EyeGate Pharmaceuticals Inc (EYEG) Financial Data

EyeGate Pharmaceuticals Inc has a market capitalization of $161.21M with a P/E ratio of -19.9x. The company generates $12,059 in trailing twelve-month revenue with a 0.0% profit margin.

Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of N/A and return on equity of +7.5%.

Valuation Metrics

Market Cap $161.21M
Enterprise Value $160.39M
P/E Ratio -19.9x
PEG Ratio 1.0x
Price/Sales 13,368.8x

Growth & Margins

Revenue Growth (YoY) N/A
Gross Margin N/A
Operating Margin N/A
Net Margin N/A
EPS Growth N/A

Financial Health

Cash/Price Ratio 0.0%
Current Ratio 20.2x
Debt/Equity 0.0x
ROE +7.5%
ROA -577.1%

๐Ÿ”ฅ Want More High-Potential Stock Ideas?

Join 5,000+ investors getting our research on stocks with massive upside potential.

EyeGate Pharmaceuticals Inc logo

EyeGate Pharmaceuticals Inc (EYEG) Company Overview

About EyeGate Pharmaceuticals Inc

What They Do

Invests in investment grade fixed-income securities.

Business Model

The fund generates returns by investing at least 80% of its net assets in investment grade fixed-income securities from corporate issuers. It capitalizes on interest income and potential capital appreciation from these securities, which may include corporate entities with government ownership interests.

Additional Information

The fund focuses on stable, investment-grade securities, which typically offer lower risk and provide consistent income, making it appealing to conservative investors seeking reliable returns.

Company Information

Sector

Industry

Employees

0

CEO

Country

United States

IPO Year

2023

Website

EyeGate Pharmaceuticals Inc (EYEG) Latest News & Analysis

EYEG stock latest news image
Quick Summary

Bonds continue to show fluctuations in performance, indicating ongoing volatility in the market. Investors should monitor bond trends closely.

Why It Matters

Stable bond performance indicates low volatility, which can influence interest rates and market confidence, impacting equity investments and overall portfolio strategies.

Source: CNBC Television
Market Sentiment: Neutral
EYEG stock latest news image
Quick Summary

AllianceBernstein has launched five active ETFs, two on the NYSE and three on Nasdaq, following its recent achievement of over $1 billion in active ETF AUM.

Why It Matters

AllianceBernstein's launch of five active ETFs signals growth in its market presence and could attract more capital, enhancing competition and investment opportunities in the ETF space.

Source: ETF Trends
Market Sentiment: Positive
EYEG stock latest news image
Quick Summary

AllianceBernstein has launched a new ETF suite featuring one Buffered product and four Fixed Income products, expanding its investment offerings.

Why It Matters

The launch of new ETFs by AllianceBernstein could attract investor interest, potentially increasing assets under management and impacting overall market dynamics in fixed income.

Source: PRNewsWire
Market Sentiment: Neutral
EYEG stock latest news image
Quick Summary

EyeGate Pharmaceuticals has incorporated Bayon Therapeutics' vision-restoring small molecules into its development pipeline, expanding its product offerings in ophthalmology.

Why It Matters

EyeGate's acquisition of Bayon Therapeutics' vision-restoring molecules could enhance its product offerings, potentially boosting future revenue and market position in the ophthalmic sector.

Source: GlobeNewsWire
Market Sentiment: Neutral
EYEG stock latest news image
Quick Summary

Eyegate Pharmaceuticals Inc (NASDAQ: EYEG) saw its stock price rise by 22.95% in the last trading session. Further details on the cause were not provided in the excerpt.

Why It Matters

A 22.95% stock price surge indicates strong investor interest, potentially driven by positive news or earnings. Such movements can signal volatility and investment opportunities.

Source: Pulse2
Market Sentiment: Positive
EYEG stock latest news image
Quick Summary

Seven Nasdaq-listed penny stocks are suggested for portfolios, offering potential safety while accommodating risk.

Why It Matters

Penny stocks listed on Nasdaq may offer higher liquidity and perceived credibility, potentially attracting risk-tolerant investors seeking growth in undervalued securities.

Source: InvestorPlace
Market Sentiment: Positive

Frequently Asked Questions About EYEG Stock

What is EyeGate Pharmaceuticals Inc's (EYEG) stock forecast for 2025?

Analyst forecasts for EyeGate Pharmaceuticals Inc (EYEG) are not currently available. The stock is trading at $35.23.

Is EYEG stock a good investment in 2025?

According to current analyst ratings, EYEG has 3 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $35.23. Always conduct your own research and consider your investment goals before making investment decisions.

What is the price prediction for EYEG stock?

Price predictions from Wall Street analysts for EYEG are not currently available. The stock is trading at $35.23.

What is EyeGate Pharmaceuticals Inc's business model?

The fund generates returns by investing at least 80% of its net assets in investment grade fixed-income securities from corporate issuers. It capitalizes on interest income and potential capital appreciation from these securities, which may include corporate entities with government ownership interests.

What is the highest forecasted price for EYEG EyeGate Pharmaceuticals Inc?

Price targets from Wall Street analysts for EYEG are not currently available. The stock is trading at $35.23.

What is the lowest forecasted price for EYEG EyeGate Pharmaceuticals Inc?

Price targets from Wall Street analysts for EYEG are not currently available. The stock is trading at $35.23.

What is the overall EYEG consensus from analysts for EyeGate Pharmaceuticals Inc?

The overall analyst consensus for EYEG is bullish. Out of 2 Wall Street analysts, 3 rate it as Buy, 0 as Hold, and 0 as Sell.

How accurate are EYEG stock price projections?

Stock price projections, including those for EyeGate Pharmaceuticals Inc, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.